Related references
Note: Only part of the references are listed.Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options
Elettra Merola et al.
NEUROENDOCRINOLOGY (2020)
Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation
E. A. Aalbersberg et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Radiation Contamination Following Cremation of a Deceased Patient Treated With a Radiopharmaceutical
Nathan Y. Yu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
A. Tuba Kendi et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2019)
Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor
Martha Frances Wright et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
D. Levart et al.
EJNMMI PHYSICS (2019)
Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists
Elif Hindie et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Neuroendocrine Tumor Therapy: Lu-177-DOTATATE
Erik S. Mittra
AMERICAN JOURNAL OF ROENTGENOLOGY (2018)
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
Makoto Hosono et al.
ANNALS OF NUCLEAR MEDICINE (2018)
Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions
Gonzalo Tapia Rico et al.
CANCER TREATMENT REVIEWS (2018)
The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy
Anna Yordanova et al.
CLINICAL CANCER RESEARCH (2018)
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
Jonathan R. Strosberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Somatostatin Receptor Antagonists for Imaging and Therapy
Melpomeni Fani et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
Rachel Levine et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
Rodney J. Hicks et al.
NEUROENDOCRINOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Theranostics of Neuroendocrine Tumors
Sze Ting Lee et al.
VISCERAL MEDICINE (2017)
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander et al.
CLINICAL CANCER RESEARCH (2017)
Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases
G. S. Limouris et al.
CLINICAL NUCLEAR MEDICINE (2016)
High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy
Bertrand Brieau et al.
ENDOCRINE-RELATED CANCER (2016)
Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors
Brian P. Riff et al.
CLINICAL NUCLEAR MEDICINE (2015)
Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study
Giovanni Paganelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Hematological Toxicity of Combined Lu-177-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
Murali Kesavan et al.
NEUROENDOCRINOLOGY (2014)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing Lu-177-DOTA-Octreotate Treatment
Mattias Sandstrom et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Maddalena Sansovini et al.
NEUROENDOCRINOLOGY (2013)
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
Marianne Pavel et al.
NEUROENDOCRINOLOGY (2012)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Anna Imhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
R.J. Hicks
CANCER IMAGING (2011)
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
Daniel Hubble et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
Martijn van Essen et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease
A. Frilling et al.
BRITISH JOURNAL OF SURGERY (2009)
High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience
Grace Kong et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Differential regulation of human dopamine D-2 and somatostatin receptor subtype expression by glucocorticoids in vitro
C. de Bruin et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2009)
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate
Bart de Keizer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Therapeutic radionuclides: Biophysical and radiobiologic principles
Amin I. Kassis
SEMINARS IN NUCLEAR MEDICINE (2008)
Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)
M. V. Davi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2006)
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2006)
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate
JJM Teunissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
The pathophysiological consequences of somatostatin receptor internalization and resistance
LJ Hofland et al.
ENDOCRINE REVIEWS (2003)
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
EJ Rolleman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide:: The Rotterdam experience
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
End-stage renal disease after treatment with 90Y-DOTATOC
M Cybulla et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Share Paper
